Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 8/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343451 | 1.00 | SCN9A (0.61) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4333702 | 0.82 | PIK3CA (0.63) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4333700 | 0.82 | PIK3CA (0.63) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4033200 | 0.79 | PIM1 (0.67) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4209957 | 0.79 | PIM1 (0.67) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4033197 | 0.79 | PIM1 (0.67) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4540360 | 0.79 | SCN9A (0.71) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL4033254 | 0.79 | SCN9A (0.71) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL6202184 | 0.78 | PIM1 (0.76) | SCN9AAKR1B1MEN1POLBKMT2A | |
| SCHEMBL3910112 | 0.76 | AKR1B1 (1.00) | AKR1B1MEN1POLBKMT2APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | SCN9A 4531/4885AKR1B1 1516/4885MEN1 229/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | SCN9A 4531/4885AKR1B1 1516/4885MEN1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.